Kazia Therapeutics Beta
Qual é o Beta de Kazia Therapeutics?
O Beta de Kazia Therapeutics Limited é 2.85
Qual é a definição de Beta?
BETA indica se uma ação é mais ou menos volátil do que o mercado como um todo. Um beta menor que 1 indica que o estoque é menos volátil do que o mercado, enquanto um beta maior que 1 indica que o estoque é mais volátil. A volatilidade é medida como a flutuação do preço em torno da média.
Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.
Beta de empresas na Setor Health Care em ASX em comparação com Kazia Therapeutics
O que Kazia Therapeutics faz?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Empresas com beta semelhantes a Kazia Therapeutics
- Score Media And Gaming Inc tem Beta de 2.84
- Windfall Geotek tem Beta de 2.84
- Windfall Geotek tem Beta de 2.84
- Tamarack Valley tem Beta de 2.84
- Ignite tem Beta de 2.84
- Nuvei tem Beta de 2.85
- Kazia Therapeutics tem Beta de 2.85
- Ferrellgas Partners tem Beta de 2.85
- Noble Mineral Exploration tem Beta de 2.85
- NRG Metals tem Beta de 2.86
- Westport Fuel Systems tem Beta de 2.86
- Green Organic Dutchman tem Beta de 2.86
- Bloom tem Beta de 2.86